Esomeprazole + Budesonide
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Eosinophilic Esophagitis
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE, GERD
Trial Timeline
May 1, 2008 → Dec 1, 2010
NCT ID
NCT00728481About Esomeprazole + Budesonide
Esomeprazole + Budesonide is a phase 2/3 stage product being developed by AstraZeneca for Eosinophilic Esophagitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00728481. Target conditions include Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00728481 | Phase 2/3 | Completed |
Competing Products
20 competing products in Eosinophilic Esophagitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KHK4563 + KHK4563 + KHK4563 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| benralizumab + benralizumab + Placebo | Kyowa Kirin | Phase 2 | 52 |
| SHR-1703 + SHR-1703 Placebo | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| NS-229 + Placebo | Nippon Shinyaku | Phase 2 | 52 |
| Tezepelumab + Tezepelumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Approved | 85 |
| Cohort | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + Matching placebo | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab + Mepolizumab + Placebo to Mepolizumab + Placebo to Benralizumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab Prefilled Syringe | AstraZeneca | Approved | 85 |
| benralizumab | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |
| Tezepelumab + Placebo | AstraZeneca | Phase 2 | 52 |
| Benralizumab + Placebo | AstraZeneca | Phase 2/3 | 65 |
| inhaled/swallowed budesonide + viscous/swallowed budesonide | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + 129 Xenon | AstraZeneca | Pre-clinical | 23 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |